EUVIMEDEUVIMED entdecken
Fallbericht

An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy

Sihui Zhu, Chenxi Liu, Yunchen Jin, Hailong Zhang, Mingzhen Zhou, Chen Xu, Jie Shao, Qin Liu, Jia Wei, Jie Shen, Baorui Liu

Inflammation · 2024

DOI: 10.1007/s10753-024-02003-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Inflammation, 2024. Verfasst von Sihui Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Cancer Centre, Department of Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Z…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Immunotherapy, Bile Duct Neoplasms, Precision Medicine. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of Nanjing University of Chinese Medicine, The Hospital Management Research of Nanjing Drum Tower Hospital, Medical Research of Jiangsu Health Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced intrahepatic cholangiocarcinoma (ICC) is a highly aggressive malignancy characterized by limited response to standard therapeutic modalities, such as radiotherapy, chemotherapy, and targeted therapy. The prognosis for patients with advanced ICC is exceedingly bleak, with an overall survival of less than 1 year. In recent years, personalized neoantigen vaccines have emerged as a promising approach to augment the immune response against tumors. Clinical investigations are currently underway to evaluate the efficacy of neoantigen-based peptide, DNA, and dendritic cell vaccines. Herein, we present a noteworthy case of advanced ICC patients who experienced disease progression following relapse and subsequently received immunotherapy with a personalized neoantigen nanovaccine. This innovative treatment strategy involved the administration of a custom-designed neoantigen-based peptide nanovaccine tailored to the patient's specific gene mutation profile subsequent to failure of first-line therapy. The clinical efficacy and anti-tumor immune responses were evaluated using various methods, including imaging, interferon-γ ELISPOT assay, and intracellular cytokine staining. Notably, the neoantigen nanovaccine elicited a robust and specific tumor-killing effect mediated by T cells, resulting in a durable response lasting up to 25 months. These findings highlight the potential of neoantigen-based immunotherapy as a novel therapeutic avenue for the management of advanced ICC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaImmunotherapyBile Duct NeoplasmsPrecision MedicineCancer VaccinesAntigens, NeoplasmHumansMaleMiddle Aged

Stichwörter der Autor:innen

ImmunotherapyIntrahepatic cholangiocarcinomaPersonalized neoantigen nano-vaccine

Substanzen

Cancer VaccinesAntigens, Neoplasm

Autor:innen und Institutionen

  • Comprehensive Cancer Centre, Department of Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Jiangsu Province, 210008, Nanjing, China.
  • Comprehensive Cancer Centre of Nanjing International Hospital, Medical School of Nanjing University, Nanjing, China.
  • Clinical Cancer Institute of Nanjing University, 321 Zhongshan Road, Jiangsu Province, 210008, Nanjing, China.
  • Department of Radiology of Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
  • Comprehensive Cancer Centre, Department of Oncology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Jiangsu Province, 210008, Nanjing, China. shenjie2008nj…
  • Clinical Cancer Institute of Nanjing University, 321 Zhongshan Road, Jiangsu Province, 210008, Nanjing, China. shenjie2008nju@163.com.

Förderung

  • National Natural Science Foundation of Nanjing University of Chinese Medicine
  • The Hospital Management Research of Nanjing Drum Tower Hospital
  • Medical Research of Jiangsu Health Committee

Zitieren

APA

Zhu, S., Liu, C., Jin, Y., Zhang, H., Zhou, M., Xu, C., Shao, J., Liu, Q., Wei, J., Shen, J., & Liu, B. (2024). An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy. Inflammation. https://doi.org/10.1007/s10753-024-02003-8

Vancouver

Zhu S, Liu C, Jin Y, Zhang H, Zhou M, Xu C, et al. An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy. Inflammation. 2024. doi:10.1007/s10753-024-02003-8

BibTeX
@article{Zhu2024,
  author = {Zhu, Sihui and Liu, Chenxi and Jin, Yunchen and Zhang, Hailong and Zhou, Mingzhen and Xu, Chen and Shao, Jie and Liu, Qin and Wei, Jia and Shen, Jie and Liu, Baorui},
  title = {An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy},
  journal = {Inflammation},
  year = {2024},
  doi = {10.1007/s10753-024-02003-8}
}
Kostenlos starten →